Methods and results
We conducted a telephone survey of all the occupational health departments and on-duty general surgical and orthopaedic registrar grade surgical trainees in the South and West region. Separate sets of questions were used for occupational health departments and surgical trainees (box).
Eleven occupational health departments were surveyed in September 1998. All the departments were aware of the Department of Health's guidelines, and all had either implemented a local policy (10) or nearly completed implementation (1) . All local policies offered triple therapy 24 hours a day for healthcare workers occupationally exposed to HIV. Nineteen healthcare workers presented for consideration of post-exposure prophylaxis, of whom 3 declined treatment, 7 stopped the course early because of low risk of HIV infection in the source, and 9 completed the course.
Twenty six surgeons (13 orthopaedic, 13 general surgery) were surveyed in 13 hospitals. Only 8 surgeons knew of the Department of Health's guidelines on post-exposure prophylaxis; 10 were aware that local guidelines existed, but only 2 of these were familiar with the local recommendations. The time within which prophylaxis should be obtained was correctly stated as one hour by 10 surgeons; 9 surgeons thought that post-exposure prophylaxis should be obtained within 24 hours, 3 (12%) within 72 hours, and 4 did not know. Only 2 surgeons knew where to obtain post-exposure prophylaxis out of hours. No surgeons knew the correct estimated risk of seroconversion after a needlestick injury from an HIV positive patient. The incorrect responses were as low as 0.0025% and as high as 100%, although 13 estimated a < 1% risk. The risk was estimated as < 0.3% by 5 surgeons, 0.3% to < 1% by 8, 1-5% by 7, 5-50% by 3, and 50-100% by 2; 1 surgeon did not hazard an estimate.
Comment
Most of the occupational health departments in the South and West region, in accordance with the Department of Health's guidelines, had local policies for risk assessment and counselling, 24 hour availability of post-exposure prophylaxis, and follow up protocols. However, despite national and local publicity, surgeons in the region were poorly informed about these guidelines, and their knowledge about percutaneous exposure to HIV was inadequate.
The risk of seroconversion to HIV after a percutaneous exposure may be increased if a large volume of infectious material is transferred or if the viral titre in the material is high.
4 Antiretroviral treatment reduces the ability of the virus to replicate, allowing the intact immune system an opportunity to clear the virus and thereby reduce the risk of seroconversion. Treatment with zidovudine has been shown to reduce the risk of seroconversion by 80%. 4 The use of triple antiretroviral therapy is thought to reduce further the risk of transmission and prevent an increase in zidovudine resistance.
It is important that information about percutaneous exposure to HIV and appropriate prophylactic treatment is circulated to surgeons effectively, especially as the recommended prophylaxis needs to be given within one hour of exposure. Further work is necessary to determine national trends in both the implementation of the Department of Health's guidelines and surgeons' awareness of them.
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Competing interests: None declared. We report two cases of a suspected interaction between clindamycin and cyclosporin. Case 1 was in a 48 year old woman with 1 -antitrypsin deficiency who had right sided single lung transplantation for end stage pulmonary emphysema. After B cell lymphoma affecting the transplanted lung was diagnosed, immunosuppression was reduced to a target concentration of cyclosporin of 100-150 g/l. Owing to bronchopulmonary infection with Staphylococcus aureus, treatment with oral clindamycin 600 mg thrice daily was begun. Serum cyclosporin concentrations fell continuously so the daily dose was increased. After clindamycin treatment was stopped cyclosporin was reduced to the same dose as before antibiotic treatment (figure).
Case 2 was in a 39 year old woman with cystic fibrosis who developed bilateral pneumonia seven weeks after double lung transplantation. Bronchoalveolar washings showed S aureus. Antibiotic treatment with oral clindamycin 600 mg thrice daily was started. Over four weeks the dose of cyclosporin was continuously increased from 325 mg to 1100 mg daily to maintain serum concentrations around 200 g/l. After clindamycin treatment was stopped the dose of cyclosporin was reduced to the same dose as before antibiotic treatment (figure).
Cyclosporin is extensively metabolised by the liver. Therefore, circulating cyclosporin concentrations may be influenced by drugs such as macrolide antibiotics which affect hepatic microsomal enzymes, particularly the cytochrome P-450 system. 1 2 However, we did not find any reports of an effect of clindamycin on the P-450 pathway in literature databases or the manufacturer's medical event reporting system (Pharmacia Upjohn, personal communication). The oral bioavailability of cyclosporin depends on the intestinal P-glycoprotein (mdr1), which partly explains the large variation in daily dose of cyclosporin required among transplant recipients.
